Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts

Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts

Abstract Background Disease‐related variants in PHEX cause XLH by an increase of fibroblast growth factor 23 (FGF23) circulating levels, resulting in hypophosphatemia and 1,25(OH)2 vitamin D deficiency. XLH manifests in early life with rickets and persists in adulthood with osseous and extraosseous...

Full description

Bibliographic Details
Main Authors: Maria Helena Vaisbich, Antônio César Paulillo deCillo, Bárbara Campolina C. Silva, Catarina Brasil DÁlva, Érico Higino deCarvalho, Juliana M. C. M. deAlmeida, Larissa L. M. Marques, Marcia Ribeiro, Mauro Borghi M. daSilva, Paula Frassinetti V. deMedeiros, Pedro Henrique Mendes
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Molecular Genetics & Genomic Medicine
Subjects:
adulthood
burosumab
FGF23
hyperparathyroidism
PHEX variants
X‐linked hypophosphatemia
Online Access:https://doi.org/10.1002/mgg3.2387

Internet

https://doi.org/10.1002/mgg3.2387

Similar Items